ConductScience.org, home

Paper392602

The mechanism of action of antitumor platinum compounds.

Roberts JJ and 1 other. Prog Nucleic Acid Res Mol Biol, 1979. Cited by 248 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. The mechanism of action of antitumor platinum compounds. Papers, record 392602. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/392602

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The mechanism of action of antitumor platinum compounds.
PubMed
Journal
Prog Nucleic Acid Res Mol Biol
PubMed
Year
1979
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
248
iCite
Relative citation ratio, by iCite
6.51
iCite
Revised in PubMed
2019-10-28
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Roberts JJJ J
2Thomson AJA J

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
DNA, NeoplasmMajor topic
PlatinumMajor topic
Animals
Cisplatin
DNA
DNA Repair
Escherichia coli
Humans
Ligands
Mammals
Structure-Activity Relationship

Source PubMed

Download CSV of topics

Cited by66

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 248 citations.

PMIDTitleJournalYearIn PapersSource
42269607DNA repair drives cisplatin-induced neuronal death.Cell2026https://conductscience.org/library/papers/42269607PubMed
41273305Computational Analysis of a Next-Generation Platinum-Based Chemotherapies that Induce DNA Double-Strand Breaks.J Chem Inf Model2026https://conductscience.org/library/papers/41273305PubMed
40985211Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs.Chem Rev2025https://conductscience.org/library/papers/40985211PubMed
37071737Next Generation Gold Drugs and Probes: Chemistry and Biomedical Applications.Chem Rev2023https://conductscience.org/library/papers/37071737PubMed
35806229Pro-Inflammatory Signalling PRRopels Cisplatin-Induced Toxicity.Int J Mol Sci2022https://conductscience.org/library/papers/35806229PubMed
35631926DNA Conformational Changes Induced by Its Interaction with Binuclear Platinum Complexes in Solution Indicate the Molecular Mechanism of Platinum Binding.Polymers (Basel)2022https://conductscience.org/library/papers/35631926PubMed
32354124Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?Cancers (Basel)2020https://conductscience.org/library/papers/32354124PubMed
28724953Antimicrobial Efficacy and Synergy of Metal Ions against Enterococcus faecium, Klebsiella pneumoniae and Acinetobacter baumannii in Planktonic and Biofilm Phenotypes.Sci Rep2017https://conductscience.org/library/papers/28724953PubMed
23738524Monofunctional and higher-valent platinum anticancer agents.Inorg Chem2013https://conductscience.org/library/papers/23738524PubMed
22659329Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes.Pharmacol Rev2012https://conductscience.org/library/papers/22659329PubMed
19259415The anti-tumour agent, cisplatin, and its clinically ineffective isomer, transplatin, produce unique gene expression profiles in human cells.Cancer Inform2008https://conductscience.org/library/papers/19259415PubMed
18231104Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.Br J Cancer2008https://conductscience.org/library/papers/18231104PubMed
17484128Chromatin as a target for the DNA-binding anticancer drugs.Subcell Biochem2007https://conductscience.org/library/papers/17484128PubMed
15840822RNA hydrolysis and inhibition of translation by a Co(III)-cyclen complex.RNA2005https://conductscience.org/library/papers/15840822PubMed
11856483Therapeutic and analysis model of intrahepatic metastasis reflects clinical behavior of hepatocellular carcinoma.Jpn J Cancer Res2002https://conductscience.org/library/papers/11856483PubMed
11477455Cisplatin chemotherapy plus adenoviral p53 gene therapy in EBV-positive and -negative nasopharyngeal carcinoma.Cancer Gene Ther2001https://conductscience.org/library/papers/11477455PubMed
9400943Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.Br J Cancer1997https://conductscience.org/library/papers/9400943PubMed
8609067Relationship between cell-killing efficiency and number of platinum atoms binding to DNA, RNA, and protein molecules in HeLa cells treated with cis-diamine(glycolato)platinum(II).Jpn J Cancer Res1996https://conductscience.org/library/papers/8609067PubMed
8286217The role of apoptosis in cell killing by cisplatin: a flow cytometric study.Br J Cancer1994https://conductscience.org/library/papers/8286217PubMed
8033299Effects of intralesional injection of cisplatin dissolved in urografin and lipiodol on Ehrlich ascites tumor and normal tissues of CD-1 mice.Cancer Chemother Pharmacol1994https://conductscience.org/library/papers/8033299PubMed

See all 66 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/392602

GET https://conductscience.org/api/papers/v1/392602/cited_by?page=2